Tarloxotinib

Drug Profile

Tarloxotinib

Alternative Names: Hypoxin™; PR 610; Tarloxotinib bromide; TH-4000

Latest Information Update: 03 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator University of Auckland
  • Developer Proacta; Threshold Pharmaceuticals
  • Class Antineoplastics
  • Mechanism of Action Epidermal growth factor receptor antagonists; Protein tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Non-small cell lung cancer; Solid tumours; Squamous cell cancer

Most Recent Events

  • 03 Aug 2017 Chemical structure information added
  • 29 Jun 2017 Tarloxotinib is available for licensing as of 29 Jun 2017. http://www.thresholdpharm.com/overview-1/
  • 15 Dec 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top